Patents by Inventor Takehiko Nakamura

Takehiko Nakamura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics
    Publication number: 20070065435
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • Gamma-1 And Gamma-3 Anti-Human CD23 Monoclonal Antibodies And Use Thereof As Therapeutics
    Publication number: 20070065434
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: August 7, 2006
    Publication date: March 22, 2007
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • ?-1 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 7033589
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: April 25, 2006
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Publication number: 20060073147
    Abstract: Methods for inhibiting production of IgE in a human subject with an IgE-mediated allergic disorder by administering anti-CD23 antibodies.
    Type: Application
    Filed: September 21, 2005
    Publication date: April 6, 2006
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Publication number: 20050118175
    Abstract: Methods for inhibiting IgE production in a human subject using anti-CD23 antibodies.
    Type: Application
    Filed: December 6, 2004
    Publication date: June 2, 2005
    Applicant: Biogen Idec MA Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Patent number: 6893636
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Grant
    Filed: February 5, 1998
    Date of Patent: May 17, 2005
    Assignee: Biogen Idec MA Inc.
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Publication number: 20050054833
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: September 28, 2004
    Publication date: March 10, 2005
    Applicant: Biogen Idec Inc.
    Inventors: Mitchell Reff, William Kloetzer, Takehiko Nakamura
  • GAMMA-1 AND GAMMA-3 ANTI-HUMAN CD23 MONOCLONAL ANTIBODIES AND USE THEREOF AS THERAPEUTICS
    Publication number: 20030086921
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: February 5, 1998
    Publication date: May 8, 2003
    Inventors: MITCHELL E. REFF, WILLIAM S. KLOETZER, TAKEHIKO NAKAMURA
  • Gamma-1 and gamma-3 anti-human CD23 monoclonal antibodies and use thereof as therapeutics
    Publication number: 20030059424
    Abstract: Monoclonal antibodies which specifically bind human CD23, the low affinity receptor for IgE (FceRII/CD23), and contain either a human gamma-1 or human gamma-3 constant domain, are disclosed. The antibodies are useful for modulating or inhibiting induced IgE expression. Accordingly, they have practical utility in the treatment or prophylaxis of disease conditions wherein inhibition of induced IgE production is therapeutically desirable, including allergic conditions, autoimmune diseases and inflammatory diseases.
    Type: Application
    Filed: March 25, 2002
    Publication date: March 27, 2003
    Applicant: IDEC Pharmaceutical Corporation
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Gamma-1 anti-human CD23 monoclonal antibodies
    Patent number: 6011138
    Abstract: Anti-human CD23 monoclonal antibodies containing human gamma 1 constant domains and therapeutic uses are provided. These antibodies inhibit IL-4 induced IgE production by B-cells significantly greater than antibodies containing other constant domains.
    Type: Grant
    Filed: February 20, 1997
    Date of Patent: January 4, 2000
    Assignees: IDEC Pharmaceuticals Corporation, Seikagaku Corporation
    Inventors: Mitchell E. Reff, William S. Kloetzer, Takehiko Nakamura
  • Synergistic insecticidal compositions
    Patent number: 5631285
    Abstract: Compounds comprised of 2-(4-tert-butylphenoxy) cyclohexyl prop-2-ynyl sulfite and a synthetic pyrethroid exhibit synergistic pesticidal activity.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: May 20, 1997
    Assignee: Uniroyal Chemical Company
    Inventors: Masaaki Kataoka, Akira Wakai, Takehiko Nakamura
  • Synergistic insecticidal compositions
    Patent number: 5534543
    Abstract: Compounds comprised of 2-(4-tert-butylphenoxy) cyclohexy1 prop-2-ynyl sulfite and a synthetic pyrethroid exhibit synergistic pesticidal activity.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: July 9, 1996
    Assignee: Uniroyal Chemical Company, Inc.
    Inventors: Masaaki Kataoka, Akira Wakai, Takehiko Nakamura
  • Synergistic insecticidal compositions
    Patent number: 5491168
    Abstract: Compounds comprised of 2-(4-tert-butylphenoxy) cyclohexyl prop-2-ynyl sulfite and a synthetic pyrethroid exhibit synergistic pesticidal activity.
    Type: Grant
    Filed: February 22, 1994
    Date of Patent: February 13, 1996
    Assignee: Uniroyal Chemical Company, Inc.
    Inventors: Masaaki Kataoka, Akira Wakai, Takehiko Nakamura